Clinical trials: Renin Angiotensin Aldosterone System
Hyperparathyroidism
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
This study will evaluate whether commonly used blood pressure medications called "ACE inhibitors" can lower parathyroid hormone.
- Trial name
- RAAS-PARC (NCT01691781)
- Testing
- Lisinopril
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Chronic Kidney Disease, Proteinuria
The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria
The main purpose of the study is to compare the effects of three different types of RAAS blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.
- Trial name
- NCT01541267
- Testing
- aliskiren, eplerenon, telmisartan
- Volunteers
- 20 people
- Sponsor
- Medical University of Gdansk
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Abdominal
Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity
R2C2 study has shown that abdominal obesity is associated with a cardiac and vascular remodelling in healthy volunteers. This remodelling is correlated with renin-angiotensin aldosterone system (RAAS) activation and/or systemic…
- Trial name
- R2C2-II (NCT01716819)
- Testing
- Urine sample, Blood sample, Assessment of sleep apnea syndrome
- Where
- France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Hyperaldosteronism, Hypertension
Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn
WHYSKI is a prospective within-patient observational clinical study designed to test the hypothesis that alterations of Na+, K+, water, and the lympho-angiogenetic transcription factor Tonicity Enhancing Binding Protein (TonEBP)…
- Conditions
- Hyperaldosteronism, Hypertension, Aldosterone-producing Adenoma, Aldosteronism
- Trial name
- WHYSKI (NCT06090617)
- Testing
- Skin Biopsy, Video-laparoscopic adrenalectomy
- Where
- Italy
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Hospital Padova
Microalbuminuria
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria…
- Trial name
- END-IT (NCT00907374)
- Testing
- benazepril
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Charles Drew University of Medicine and Science
COVID-19, SARS-CoV 2
COVID-19 Survival - The COVIVA Study
The COVID-19 pandemic poses a major and imminent challenge for health care systems regarding patient triage and allocation of limited resources worldwide.
- Trial name
- COVIVA (NCT04366765)
- Where
- Switzerland
- Volunteers
- 1,325 people
- Sponsor
- University Hospital, Basel, Switzerland
Obesity
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
- Trial name
- NCT00685945
- Testing
- Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy
The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with…
- Trial name
- Sema-RMA (NCT06555146)
- Testing
- Semaglutide, 0.5 mg/mL
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Bispebjerg Hospital
Hypertension
Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure).
- Trial name
- NCT01009944
- Testing
- Lisinopril, Atenolol
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Hypertension
Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension
The purpose of this study is to determine the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren in patients with mild to moderate hypertension.
- Trial name
- NCT00933920
- Testing
- Aliskiren
- Where
- 5 sites in India
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Proteinuria
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
The main purpose of the study is find whether the addition of aldosterone antagonist, spironolactone to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II…
- Trial name
- NCT00528385
- Testing
- Spironolactone (Spironol) 25 mg
- Sponsor
- Medical University of Gdansk
Hypertension Resistant to Conventional Therapy
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
A randomized clinical trial comparing sequential nephron blockage (SNB) with dual blockade of the renin-angiotensin system (RAAS) plus bisoprolol (DBB) in the treatment of resistant arterial hypertension (RH) was designed to…
- Trial name
- ResHypOT (NCT02832973)
- Testing
- Spironolactone, Furosemide,, Amiloride
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Sao Jose do Rio Preto Medical School
Diabetic Nephropathy, Diabetic Retinopathy
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
This is a prospective, multicenter, randomized, double blind, placebo-controlled and a prospective observational study. This study will be conducted at 15 study centers in various European countries.
- Trial name
- PRIORITY (NCT02040441)
- Testing
- Spironolactone, Standard care
- Where
- 15 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,777 people
- Sponsor
- Peter Rossing
Diabetes Mellitus, Type 2, Arterial Hypertension
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
- Conditions
- Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes
- Trial name
- GliRACo1 (NCT03917758)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Hypertension
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs.
- Trial name
- NCT00939588
- Testing
- Aliskiren/ Valsartan, Telmisartan/ Ramipril
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure, Low Cardiac Output
Losartan in Decompensated Heart Failure
The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial.
- Trial name
- NCT01857999
- Testing
- Losartan
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- InCor Heart Institute
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Pharmacogenomic Study of Candesartan in Heart Failure
The purpose of this study is to evaluate the impact of genetic variations on the response to candesartan in patients with heart failure who are already treated with an ACE inhibitor.
- Trial name
- NCT00400582
- Testing
- Candesartan up to 32 mg daily
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Montreal Heart Institute